Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo

BACKGROUND: The BCL-2-specific BH3-mimetic ABT-199 (venetoclax) has been reported to be principally active against favourable-risk multiple myeloma (MM) cells, prompting efforts to extend its activity to include more resistant, higher-risk MM subsets. METHODS: Effects of the CDK9 inhibitor flavopiri...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Zhou, Liang, Zhang, Yu, Sampath, Deepak, Leverson, Joel, Dai, Yun, Kmieciak, Maciej, Nguyen, Matthew, Orlowski, Robert Z, Grant, Steven
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2018
Matèries:
Translational Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5808038/
https://ncbi.nlm.nih.gov/pubmed/29241222
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.432
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars